Two investigational antitumor agents work better together against MPNST and neuroblastoma

February 9, 2017, Nationwide Children's Hospital

Two investigational agents, Aurora A kinase inhibitor (alisertib) and HSV1716, a virus derived from HSV-1 and attenuated by the deletion of RL1, have shown some antitumor efficacy in early clinical trials as monotherapies. A new study published last week in Oncotarget, however, demonstrates that the combined usage of the agents results in significantly increased antitumor efficacy in models of malignant peripheral nerve sheath tumor (MPNST) and neuroblastoma."We chose to investigate this combination in MPNST and neuroblastoma because these are two difficult-to-treat sarcomas that have shown susceptibility to these agents individually," explains Timothy Cripe, MD, PhD, division chief of Hematology/Oncology & BMT at Nationwide Children's Hospital and senior author on the study. "MPNST is a rare pediatric cancer, but for patients with neurofibromatosis 1, a genetic cancer predisposition disorder, it is the leading cause of death. More importantly, MPNST is resistant to chemotherapy."

According to Dr. Cripe, who is also a principal investigator in the Center for Childhood Cancer and Blood Diseases in The Research Institute at Nationwide Children's, many mechanisms likely worked synergistically to increase the antitumor effect in this study. Particularly, HSV1716 increased the sensitivity of uninfected cells to alisertib cytotoxicity. Second, alisertib increased peak virus production and slowed virus clearance from tumors. The team also found that alisertib inhibited virus-induced accumulation of intratumoral myeloid derived suppressor cells.

"Our study shows that alisertib helps the infection phase of HSV1716 because innate immunity is impacted," says Dr. Cripe, also professor of Pediatrics at The Ohio State University College of Medicine. "It's possible that it could inhibit the second phase, the downstream immunotherapeutic effects of the virotherapy, but based on data from other studies, we don't think that is the case."

Moving forward, Dr. Cripe says that confirming the sustained immunotherapeutic benefits of HSV1716 in the presence of alisertib and building a clinical trial are important next steps in understanding how these agents work together and how they could impact care for patients.

"Our results, in the context of early trials of both substances individually that have shown safety and efficacy, support the testing of this combination in children and young adults with and MPNST," says Dr. Cripe. "As these agents continue to move through the development and approval processes, we look forward to studying them further."

Explore further: Researchers describe new type of cancer therapy

More information: Mark A. Currier et al, Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation, Oncotarget (2017). DOI: 10.18632/oncotarget.14885

Related Stories

Researchers describe new type of cancer therapy

July 27, 2016
A study conducted at Nationwide Children's Hospital has found that a new chemotherapy is effective against both pediatric and adult cancers, and that it allows other chemotherapies to more readily reach their targets. The ...

Doctors look at treating specific types of pediatric cancer with viral therapy

September 10, 2013
(Medical Xpress)—Parents do everything they can to protect their children against all of the nasty germs floating around classrooms across the country this time of year. Doctors and researchers at Nationwide Children's ...

New chemotherapy and delivery small molecule is effective against multiple cancer tumor types

September 1, 2016
Open Therapeutics announces licensing a new class of anticancer drugs from Nationwide Children's Hospital. The drug, amphiphilic amines (RCn), shows promise against mouse models of cancer, including pediatric and adult sarcomas, ...

Evidence supports blocking immune response to enhance viral therapy against solid tumors

March 13, 2013
Following several years of study, investigators have found more evidence that viral therapy to treat solid tumors can be enhanced by blocking the body's natural immune response.

New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test

May 23, 2014
A new chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated ...

Immune system may play key role in viral therapy's effectiveness against tumors

January 21, 2015
Viral therapy for childhood cancer could possibly improve if treatments such as chemotherapy do not first suppress patients' immune systems, according to findings published today in the journal Molecular Therapy—Oncolytics. ...

Recommended for you

Mutant cells colonize our tissues over our lifetime

October 18, 2018
By the time we reach middle age, more than half of the oesophagus in healthy people has been taken over by cells carrying mutations in cancer genes, scientists have uncovered. By studying normal oesophagus tissue, scientists ...

Study involving hundreds of patient samples may reveal new treatment options of leukemia

October 17, 2018
After more than five years and 672 patient samples, an OHSU research team has published the largest cancer dataset of its kind for a form of leukemia. The study, "Functional Genomic Landscape of Acute Myeloid Leukemia", published ...

A 150-year-old drug might improve radiation therapy for cancer

October 17, 2018
A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more sensitive to radiation therapy, according to a recent study led by researchers at The Ohio State University Comprehensive Cancer ...

Loss of protein p53 helps cancer cells multiply in 'unfavourable' conditions

October 17, 2018
Researchers have discovered a novel consequence of loss of the tumour protein p53 that promotes cancer development, according to new findings in eLife.

New method uses just a drop of blood to monitor lung cancer treatment

October 17, 2018
Dr. Tasuku Honjo won the 2018 Nobel Prize in physiology or medicine for discovering the immune T-cell protein PD-1. This discovery led to a set of anti-cancer medications called checkpoint inhibitors, one of the first of ...

Researcher fighting breast cancer with light therapy

October 17, 2018
When treatment is working for a patient who is fighting cancer, the light at the end of the tunnel is easier to see.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.